南微医学科技股份有限公司2025年度业绩快报公告

Core Viewpoint - The company achieved record high revenue and profit in 2025, establishing a solid foundation for growth in 2026 despite a challenging external environment [2][3]. Financial Data and Indicators - In 2025, the company reported total revenue of 319,093.19 million RMB, a year-on-year increase of 15.81% - The net profit attributable to shareholders was 57,011.40 million RMB, up 3.05% from the previous year - The net profit excluding non-recurring gains and losses was 55,712.35 million RMB, reflecting a 2.40% increase year-on-year - Total assets at the end of the reporting period were 543,404.00 million RMB, a growth of 13.69% from the beginning of the period - Shareholders' equity attributable to the parent company was 410,853.20 million RMB, increasing by 7.38% from the start of the period [2]. Operating Performance and Financial Condition - The company's revenue growth was driven by overseas business and new product launches, while domestic operations remained stable - Strategies such as localized marketing, accelerated new product launches, and cost reduction measures helped mitigate short-term pressures from centralized procurement and tariffs [3]. - The decline in profit growth was attributed to lower gross margins from key products due to centralized procurement, inventory reduction strategies, increased costs from overseas investment projects, and foreign exchange losses [3]. - The domestic centralized procurement landscape is shifting towards a balanced focus on price, quality, innovation, and supply, enhancing the company's competitive advantages [3]. - The company is advancing its overseas business from a distribution model to a localized direct sales model [3]. - For 2026, the company plans to continue its dual strategy of internationalization and innovation, focusing on new product launches and investment project implementation to drive synchronized growth in domestic and international markets [3].

MTM-南微医学科技股份有限公司2025年度业绩快报公告 - Reportify